Researchers have found that two proteins which work in tandem in the brain's blood vessels present a double whammy in Alzheimer's disease. Not only do the proteins lessen blood flow in the brain, but they also reduce the rate at which the brain is able to remove amyloid beta, the protein that builds up in toxic quantities in the brains of patients with the disease.

Researchers at the Babraham Institute near Cambridge, supported by the Alzheimer's Research Trust and the Biotechnology and Biological Sciences Research Council (BBSRC), have discovered that the brain's circuitry survives longer than previously thought in diseases of ageing such as Alzheimer's disease.

A study published in the November issue of the Journal of Alzheimer's Disease provides an insight into normal, physiological levels and association between proteins involved in development of Alzheimer's disease.

Research from the Medical Research Council (MRC) Toxicology Unit at the University of Leicester shows that nitric oxide (NO) can change the computational ability of the brain. This finding has implications for the treatment of neurodegenerative diseases such as Alzheimer's Disease and our understanding of brain function more generally.

A study published in the November issue of the Journal of Alzheimer's Disease (Volume 15:3) suggests the reliability of the Alzheimer's Disease Assessment Scale – Cognitive (ADAS-Cog) may vary and possess the ability to affect clinical trial outcomes.

Experts estimate there are at least 30 million people who are living with dementia worldwide. By the year 2050, they say there will be as many as 100 million facing the disease. VOA's Melinda Smith has details of the latest study on an ancient herbal supplement Ginkgo Biloba, which has shown some promise in previous studies, but unsuccessful in Alzheimer's disease treatment.

Saint Louis University researchers have identified a novel way of getting a potential treatment for Alzheimer's disease and stroke into the brain where it can do its work.

An over-the-counter vitamin in high doses prevented memory loss in mice with Alzheimer's disease, and UC Irvine scientists now are conducting a clinical trial to determine its effect in humans.

A team of Université Laval researchers has shown that the main neurological markers for Alzheimer's disease are exacerbated in the brains of mice fed a diet rich in animal fat and poor in omega-3s.

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), disrupt the quality of life for patients, put a tremendous burden on family caregivers, and cost society billions of dollars annually.

The team led by UBC Psychiatry Prof. Weihong Song, who is also the Jack Brown and Family Professor and Chair in Alzheimer's Disease at UBC, found that if Valproic Acid (VPA) is used as a treatment in early stages of AD memory deficit is reversed.

A popular epilepsy drug may also be beneficial in patients with Alzheimer's disease (AD), according to a new study to be published on October 27 in the Journal of Experimental Medicine. The anti-seizure drug valproic acid improved memory and reduced brain lesions in mice with an AD-like disease.